Clinical trials for professionals
Learn about our available clinical trials
-
14 de january de 2022PamplonaIn recruitment
MO42541 Clinical trial of Atezolizumab with Lenvatinib or Sorafenib in hepatocellular carcinoma previously treated with Atezolizumab and Bevacizumab.
The aim of this study is to compare the effects, good or bad, of atezolizumab combined with one of two oral drugs (lenvatinib or sorafenib) compared to receiving only one of these oral drugs (lenvatinib or sorafenib) in people with HCC whose disease has progressed after a first line of treatment with atezolizumab plus bevacizumab. -
14 de january de 2022MadridIn recruitment
-
3 de january de 2022PamplonaIn recruitment
ARC-9 Phase Ib/II, unblinded, randomized, platform clinical trial to evaluate the safety and efficacy of therapeutic combinations of AB928 in patients with metastatic colorectal cancer.
The goal of this study is to help the developer learn whether the investigational drug, called etruma (AB928), which has not yet been approved for use, is safe and effective as part of a polytherapy for the potential treatment of mRCC. -
3 de january de 2022PamplonaIn recruitment
ALXN1840-WD-302 Clinical trial of ALXN1840 compared to treatment as usual in participants with Wilson's disease.
This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ALXN1840 compared to treatment as usual (TAU) in pediatric participants with Wilson's disease (WD) aged 3 to <18 years at inclusion. Participants may not have received any prior treatment or have been undergoing any approved usual treatment for WD (penicillamine, trientine, zinc). -
3 de january de 2022In recruitment
-
3 de january de 2022PamplonaIn recruitment
WO39608 Study of multiple immunotherapy-based treatment combinations in patients with metastatic pancreatic ductal adenocarcinoma.
The purpose of this study is to compare the effects, good or bad, on the patient and on pancreatic cancer of combinations of ATIs and conventional treatment in order to find out which treatment is best. The ATI combinations are experimental drug treatments, which means that they are not approved by the health authorities for the treatment of pancreatic cancer. -
3 de january de 2022MadridIn recruitment
BO43328 Clinical trial of multiple treatment combinations in patients with melanoma (morpheus-melanoma).
The goal of this study is to compare the effects, good or bad, that ITA treatments or treatment combinations have on you and your skin cancer, in order to know which treatment is better -
3 de january de 2022PamplonaIn recruitment
KRT-232-112 Clinical trial to assess the safety and efficacy of KRT-232 in subjects with relapsed or refractory small cell lung cancer (SCLC).
The objective of this study is to evaluate whether KRT-232 is well tolerated when administered to participants with MPC and whether KRT-232 can improve MPC. -
3 de january de 2022PamplonaIn recruitment
TAK-935-3002 Clinical trial of soticlestat as adjuvant treatment in pediatric and adult subjects with Lennox-Gastaut syndrome (LGS).
The purpose of this study is to determine the following: ¿ Effects of soticlestat in reducing the frequency of major motor drop seizures (CMI; seizures due to increased or decreased muscle contraction) when given with other antiepileptic treatments. ¿ Safety of soticlestat in people with SLG by monitoring for side effects. ¿ Variations in total seizure frequency of all types after receiving soticlestat. ¿ Blood concentration of soticlestat over time. ¿ Effects ... -
3 de january de 2022PamplonaIn recruitment
CC-92328-MM-001 Clinical, multicenter, open-label, dose-finding trial of CC-92328 in subjects with relapsed and/or refractory multiple myeloma.
The objective of this study is to determine the safety (any side effects) and define the appropriate dose of the investigational drug, CC-92328, also known as DF3001 and BMS]986392. CC-92328 has not been approved for the treatment of multiple myeloma or any other disease and its use in this study is investigational. In this study, CC-92328 is being administered to humans for the first time.